Eisai/Biogen Maintain Lead Over Lilly In New Race To Alzheimer’s Approval
Full Approval Filing May Quickly Follow Accelerated US FDA Decision
Executive Summary
The US FDA accepted an application for accelerated approval and set a 6 January action date, giving lecanemab ample time to reach the market ahead of Lilly’s competing anti-amyloid antibody donanemab.
You may also be interested in...
ICER Sets Ceiling For Anti-Amyloid Pricing; Will Eisai And Lilly Raise The Roof?
The independent drug pricing watchdog said lecanemab and donanemab would be cost-effective at $8,500-$20,600 per year, but pricing has been expected to be closer to Aduhelm’s $28,200 price tag.
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments
Lilly will increase spending, resulting in lower-than-expected EPS, to drive its revenue growth, relying on sales of new products, particularly its next generation of incretin agonists for diabetes and obesity.